Dare Bioscience

Dare Bioscience Receivables

The Accounts Receivable of Dare Bioscience (DARE) as of Oct 31, 2026 is 1.39 M USD. In the previous year, Accounts Receivable was 1.66 M USD — a change of -16.27% (lower).

Receivables

1.39 MUSD

YoY

-16.27%

Last updated:

Accounts Receivable of Dare Bioscience is 2015 1.39 M USD. Accounts Receivable of Dare Bioscience was 2014 1.66 M USD. It decreases by -16.27% lower compared to the previous year.

The Dare Bioscience Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2014
1.66 M USD
Jan 1, 2015
1.39 M USD
The Dare Bioscience Receivables history
YEARReceivablesYoY
1.39 MUSD-16.27%
1.66 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dare Bioscience Stock analysis

What does Dare Bioscience do? Daré Bioscience, Inc. develops and commercializes pharmaceutical products in women's reproductive health, focusing on non-hormonal contraceptive solutions. Its lead product, Ovaprene, is a clinical stage intravaginal ring designed to provide multi-week protection without intervention during intercourse. The ring features a permeable mesh barrier and localized spermiostatic agent delivery, combining barrier and spermicidal mechanisms to achieve efficacy comparable to diaphragms and short-acting hormonal methods like oral pills and vaginal rings. The company targets women seeking non-hormonal contraceptive options, with Ovaprene positioned as an alternative to existing hormonal products and barrier methods. The firm generates revenue through the development and commercialization of Ovaprene, aiming to address unmet needs in women's reproductive health. Ovaprene is designed to offer a non-hormonal, user-friendly alternative to traditional hormonal contraceptives, appealing to consumers who prefer avoiding hormonal side effects. The company's focus on clinical development and product commercialization aligns with the market demand for innovative, non-hormonal contraceptive options in women's health. Dare Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dare Bioscience stock

Accounts Receivable of Dare Bioscience is 1.39 M USD in 2015.

Accounts Receivable of Dare Bioscience changed from 1.66 M USD to 1.39 M USD, representing a -16.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Dare Bioscience since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Dare Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Dare Bioscience

All Key Metrics — Dare Bioscience